OOIR: Observatory of International Research

Papers

(The median citation count of Translational Neurodegeneration is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Life and disease status of patients with Parkinson’s disease during and after zero-COVID in China: an online survey	267
Exploring the skin as an open window onto neurodegenerative diseases	177
Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington’s disease mice	175
Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer’s disease mouse model	173
N6-methyladenosine-modified circRIMS2 mediates synaptic and memory impairments by activating GluN2B ubiquitination in Alzheimer's disease	162
Attenuating α-synuclein pathology in mice with in situ engineered astrocytes	161
Age-dependent removal of Atg9-containing vesicle accumulations in motoneuron disease models by physical exercise	130
The C. elegans gba-3 gene encodes a glucocerebrosidase that exacerbates α-synuclein-mediated impairments in deletion mutants	130
Retraction Note: Asiaticoside, a trisaccaride triterpene induces biochemical and molecular variations in brain of mice with parkinsonism	127
Patient-derived iPSC models of Friedreich ataxia: a new frontier for understanding disease mechanisms and therapeutic application	125
Gene therapy breakthroughs in ALS: a beacon of hope for 20% of ALS patients	120
CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease	110
Oligodendrocyte progenitor cells in Alzheimer’s disease: from physiology to pathology	97
Role of dopamine in the pathophysiology of Parkinson’s disease	94
NLRP3 inflammasome in cognitive impairment and pharmacological properties of its inhibitors	91
Axonopathy: mechanisms and potential therapeutic targets for neurodegenerative diseases	91
A novel plasma p-tau181 assay as a specific biomarker of tau pathology in Alzheimer's disease	88
Aquaporin-4 as a cerebrospinal fluid biomarker of Alzheimer’s disease	85
Correction: A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau	85
Dual modulation of amyloid beta and tau aggregation and dissociation in Alzheimer’s disease: a comprehensive review of the characteristics and therapeutic strategies	81
Parkinson’s disease and gut microbiota: from clinical to mechanistic and therapeutic studies	80
Correction: Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease	77
Cortical layer multi-parameter analysis of neurovascular impairments in AD/ADRD rodent model with in vivo optical imaging	75
Cognitive dysfunction of patients infected with SARS-CoV-2 omicron variant in Shanghai, China	75
Targeted delivery of BACE1 siRNA for synergistic treatment of Alzheimer's disease	74

Functional analysis of late-onset Alzheimer’s disease risk genes in Caenorhabditis elegans identifies regulators of neuronal aging	73
Remodeling of astrocyte secretome in amyotrophic lateral sclerosis: uncovering novel targets to combat astrocyte-mediated toxicity	72
Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures	68
ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein	60
Immunosenescence in aging and neurodegenerative diseases: evidence, key hallmarks, and therapeutic implications	58
Inflammasomes in neurodegenerative diseases	57
Nose-to-brain drug delivery: from bench to bedside	57
Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside	55
Longitudinal evolution of cortical thickness signature reflecting Lewy body dementia in isolated REM sleep behavior disorder: a prospective cohort study	54
α-Synuclein oligomers potentiate neuroinflammatory NF-κB activity and induce Cav3.2 calcium signaling in astrocytes	52
Peripheral proteinopathy in neurodegenerative diseases	52
The emerging role of furin in neurodegenerative and neuropsychiatric diseases	50
Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology	49
Microstructural integrity of the locus coeruleus and its tracts reflect noradrenergic degeneration in Alzheimer’s disease and Parkinson’s disease	47
Controversies and insights into PTBP1-related astrocyte-neuron transdifferentiation: neuronal regeneration strategies for Parkinson’s and Alzheimer’s disease	47
Transaldolase 1 contributes to pentose phosphate pathway disruption and synaptic dysfunction in Alzheimer’s disease	46
Mesenchymal stromal cells and neuroinflammation: a multimodal approach to neuroprotection and future therapeutic horizons	46
Large-scale proximity extension assay reveals CSF midkine and DOPA decarboxylase as supportive diagnostic biomarkers for Parkinson’s disease	46
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer’s disease using an indwelling CSF catheter	46
The emerging role and therapeutic targeting of autophagy-lysosome pathway in the pathogenesis of Parkinson’s disease	44
Molecular mechanisms of exercise-induced improvements in Alzheimer’s disease: a focus on lipid homeostasis	43
Multidimensional biomarkers for multiple system atrophy: an update and future directions	43
Perivascular spaces relate to the course and cognition of Huntington’s disease	42
Improving vulnerable Calbindin1− neurons in the ventral hippocampus rescues tau-induced impairment of episodic memory	41
Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseases	40
Astrocytes contribute to toll-like receptor 2-mediated neurodegeneration and alpha-synuclein pathology in a human midbrain Parkinson’s model	40
Aging-dependent YAP1 reduction contributes to AD pathology by upregulating the Nr4a1-AKT/GSK-3β axis	39
An AARS1 variant identified to cause adult-onset leukoencephalopathy with neuroaxonal spheroids and pigmented glia	38
Neuronal and synaptic adaptations underlying the benefits of deep brain stimulation for Parkinson's disease	38
Tau conformation, distribution and PET imaging correlations in progressive supranuclear palsy	38
Targeting galectin-3 to counteract spike-phase uncoupling of fast-spiking interneurons to gamma oscillations in Alzheimer’s disease	38
Cerebrospinal fluid cyclase-associated protein 2 is increased in Alzheimer’s disease and correlates with tau pathology	37
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system	37
Deficient AMPK-SENP1-Sirt3 signaling impairs mitochondrial complex I function in Parkinson’s disease model	36
Role of extracellular vesicle-carried ncRNAs in the interactive ‘dialogue’ within the brain and beyond: emerging theranostic epigenetic modifiers in brain-derived nanoplatforms	35
Impact of seed amplification assay and surface-enhanced Raman spectroscopy combined approach on the clinical diagnosis of Alzheimer’s disease	35
Ultrasensitive detection of aggregated α-synuclein using quiescent seed amplification assay for the diagnosis of Parkinson’s disease	33
TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis	32
Mapping cellular vulnerability in Parkinson’s disease using retro-AAVs and preformed α-synuclein fibrils	32
In vivo diagnosis of TDP-43 proteinopathies: in search of biomarkers of clinical use	31
Axonal tau reduction ameliorates tau and amyloid pathology in a mouse model of Alzheimer’s disease	31
Plasma proteomic signatures as predictors of dementia risk in individuals with sleep apnea: a cohort study	31
Lysophagy protects against ANXA11 amyloid fibril toxicity and propagation in FTLD	30
Extracellular PHF-tau modulates astrocyte mitochondrial dynamics and mediates neuronal connectivity	30
Emerging role of senescent microglia in brain aging-related neurodegenerative diseases	29
Metabolic regulation of microglial phagocytosis: Implications for Alzheimer's disease therapeutics	29
Pathophysiological subtypes of mild cognitive impairment due to Alzheimer’s disease identified by CSF proteomics	28
Nootropic foods in neurodegenerative diseases: mechanisms, challenges, and future	28
N-terminally acetylated Met11-Tau: a new pathological truncated Tau species with functional relevance in Alzheimer's disease	28
Alterations in sleep-activity cycles and clock gene expression across the synucleinopathy spectrum	28

Stress granules: emerging players in neurodegenerative diseases	28
Biases in α-synuclein immuno-quantitation: a core problem for basic and ancillary studies of Parkinson’s disease and multiple system atrophy	28
Linking APOE4/4 genotype to microglial lipid droplets and neurotoxicity in Alzheimer’s disease	26
Retrotransposon: an insight into neurological disorders from perspectives of neurodevelopment and aging	26
Deciphering lipid dysregulation in ALS: from mechanisms to translational medicine	26
Correction: CD2AP deficiency aggravates Alzheimer’s disease phenotypes and pathology through p38 MAPK activation	26
Intestine-derived α-synuclein initiates and aggravates pathogenesis of Parkinson’s disease in Drosophila	25
CSF biomarkers of reactive glial cells are associated with blood–brain barrier leakage and white matter lesions	25
Pathological insights from amyotrophic lateral sclerosis animal models: comparisons, limitations, and challenges	25
Myelin repair in Alzheimer’s disease: a review of biological pathways and potential therapeutics	25
DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson’s disease	25
Argyrophilic grain disease is common in older adults and may be a risk factor for suicide: a study of Japanese forensic autopsy cases	24
Microglia in the crosstalk between peripheral and central nervous systems in Parkinson’s disease	24
Correction: Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia	24
Increased cysteinyl-tRNA synthetase drives neuroinflammation in Alzheimer’s disease	24
TRPV1 alleviates APOE4-dependent microglial antigen presentation and T cell infiltration in Alzheimer's disease	24
Endosomal traffic disorders: a driving force behind neurodegenerative diseases	23
Disease–disease interactions: molecular links of neurodegenerative diseases with cancer, viral infections, and type 2 diabetes	23
GCN2 inhibition reduces mutant SOD1 clustering and toxicity and delays disease progression in an amyotrophic lateral sclerosis mouse model	22
Positive modulation of sigma-1 receptor: a new weapon to mitigate disease progression in amyotrophic lateral sclerosis	22
Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s disease	22
Brain metabolism in Alzheimer’s disease: biological mechanisms of exercise	21
Glutathione oxidation in cerebrospinal fluid as a biomarker of oxidative stress in amyotrophic lateral sclerosis	20
N-terminus α-synuclein detection reveals new and more diverse aggregate morphologies in multiple system atrophy and Parkinson’s disease	20
CRISPR base editing-mediated correction of a tau mutation rescues cognitive decline in a mouse model of tauopathy	20
Death-associated protein kinase 1 as a therapeutic target for Alzheimer's disease	20
Research progress on the role of extracellular vesicles in neurodegenerative diseases	20
APOE ε4-dependent effects on the early amyloid pathology in induced neurons of patients with Alzheimer’s disease	20
Critical role of ROCK1 in AD pathogenesis via controlling lysosomal biogenesis and acidification	19
Targeting the glymphatic system: Aβ accumulation and phototherapy strategies across different stages of Alzheimer’s disease	19
Transcranial alternating current stimulation (tACS) at gamma frequency: an up-and-coming tool to modify the progression of Alzheimer’s Disease	18
Alleviating the unwanted effects of oxidative stress on Aβ clearance: a review of related concepts and strategies for the development of computational modelling	18
The therapeutic potential of probucol and probucol analogues in neurodegenerative diseases	17
Beyond amyloid: nanobody-mediated neuroinflammatory therapy for Alzheimer’s disease	17
Long-term exercise enhances meningeal lymphatic vessel plasticity and drainage in a mouse model of Alzheimer's disease	17
Putative novel CSF biomarkers of Alzheimer’s disease based on the novel concept of generic protein misfolding and proteotoxicity: the PRAMA cohort	17
Toward a biomarker panel measured in CNS-originating extracellular vesicles for improved differential diagnosis of Parkinson’s disease and multiple system atrophy	17
Optogenetic induction of TDP-43 aggregation impairs neuronal integrity and behavior in Caenorhabditis elegans	17
Blockage of VEGF function by bevacizumab alleviates early-stage cerebrovascular dysfunction and improves cognitive function in a mouse model of Alzheimer’s disease	16
Plant-derived mitochondria mitigate aging-related neurodegeneration by reprogramming microglial mitochondrial energy metabolism	16
Inflammasome activation under high cholesterol load triggers a protective microglial phenotype while promoting neuronal pyroptosis	16
Protein kinase CK2α′ as a dual modulator of neuroimmune signaling and synaptic dysfunction in tauopathy	16
Employing nanoparticle tracking analysis of salivary neuronal exosomes for early detection of neurodegenerative diseases	16
Chronic subthalamic nucleus deep brain stimulation reduces pathological TrkB aggregates in a Parkinson’s disease rat model	16
Gut microbiome, cognitive function and brain structure: a multi-omics integration analysis	15
SSEA3 and CD105 positivity are associated with the treatment potency of human neural crest-derived nasal turbinate stem cells for Alzheimer’s disease	15
Dietary fasting and time-restricted eating in Huntington’s disease: therapeutic potential and underlying mechanisms	15
SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction	15
Can exercise benefits be harnessed with drugs? A new way to combat neurodegenerative diseases by boosting neurogenesis	15
Circadian disruption and sleep disorders in neurodegeneration	15
Drug repurposing for disease-modifying effects in multiple system atrophy	15
Updates in Alzheimer's disease: from basic research to diagnosis and therapies	14
Cyclooxygenase-1 deletion in 5 × FAD mice protects against microglia-induced neuroinflammation and mitigates cognitive impairment	14
Agomirs upregulating carboxypeptidase E expression rescue hippocampal neurogenesis and memory deficits in Alzheimer’s disease	14
Early GCase activity is a predictor of long-term cognitive decline in Parkinson’s disease	14